![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.60 | 20.00 | 20.50 | - | 8,874 | 10:57:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -515.00 | 89.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/8/2021 15:28 | Also on the eco med, they were still struggling with travel restrictions to work with the customers in the Philippines and Taiwan, but CEVA was back on track. | ![]() paulisi | |
23/8/2021 15:26 | The work with Ceva animal health is a positive sign for the eco med division. Working with the big names | ![]() doccash | |
23/8/2021 15:26 | Once NFV sales kick in, margins will jump. They quoted 85% on the subscription model.Also the said they were doing more proof of concept tests and further announcements would be imminent.I think they said the Romania lab was expanding into Hungary. | ![]() paulisi | |
23/8/2021 15:04 | The new all in one respiratory test will be selling in winter and that should be another money spinner. Seemed confidant of working with other big telecoms and service providers. | ![]() doccash | |
23/8/2021 14:49 | I attended the webinar and asked about the dividend.It will be announced at the AGM, but some money is going towards R&D and potential acquisitions in both divisionsNot too many questions asked, but they expect to see substantial growth on NFV. Revenue on monthly subscription basis. Expect to see it ramp up to hundreds of thousands of subscriptions in a few years time.Diagnostics is still growing and expecting to be the majority of the revenue for full year. | ![]() paulisi | |
23/8/2021 14:41 | Good man, Doc. | lsoc85 | |
23/8/2021 14:14 | From webinar | ![]() doccash | |
23/8/2021 14:13 | Dividend to be announced after AGM | ![]() doccash | |
23/8/2021 14:07 | It's not about the money received, it's about signalling his and the Board's confidence in the operation going forward. | lsoc85 | |
23/8/2021 13:49 | dividend - i didn't choose this investment for that. | ![]() nellyb | |
23/8/2021 13:16 | Nothing new in that interview.See what the webinar tells us | ![]() paulisi | |
23/8/2021 08:32 | Expecting price to dip after initial surge and probably close around 89-90pWill surge again when tipped by IC next week. | ![]() paulisi | |
23/8/2021 08:22 | According to this article, expecting revenue close to 250m | ![]() paulisi | |
23/8/2021 08:03 | Initial price up around 5% | ![]() paulisi | |
23/8/2021 08:02 | Dr Zvi Marom, Chief Executive Officer, and Moti Nagar, Chief Financial Officer, will be holding a webinar for analysts and investors today at 2.00pm BST. To register to participate, please contact Tanweer Siddique at Luther Pendragon at tanweersiddique@luth | ![]() nellyb | |
23/8/2021 07:52 | "Looking ahead, we entered the second half with a strong order book and receiving sustained demand for our diagnostic solutions. We also continue to expect to generate revenue this year from the roll-out of Edgility OS by PCCW Global. As a result, we anticipate achieving better-than-expected revenue for the full year and EBITDA to be substantially ahead of market expectations with growth of over 40% year-on-year. Consequently, and supported by a robust balance sheet, the Board of BATM continues to look to the future with great confidence. | ![]() steeplejack | |
23/8/2021 07:40 | Lot of smoke and mirrors - why could they not just take out the £13m gain and one off Oxygen profit. | ![]() zipstuck | |
23/8/2021 07:28 | Difficult to know how to interpret these results with NG Soft sale and ventilators coming out of the accounts and the impact of lockdowns.Medical division growing with NATLAB revenues to kick in and TB test coming on line.Tech side still loss making and flat on revenues, but substantial growth expected through NFV and cyberMargins significantly upPlenty of cash in the bank. No mention of dividend or bolt on acquisitionsFull year ahead of expectations.Not sure what the markets will make of it | ![]() paulisi | |
22/8/2021 23:04 | Difficulties in sourcing components may have impacted orders, no guidance on divi, no major new contracts announced, not sure what tomorrow will bring. | ![]() picsous |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions